On June 23, Sino Biopharmaceutical rose 3.15% in regular trading, trading at HK$4.58/share, with turnover of approximately HK$45.24 million.

On the news front, the pharmaceutical sector staged a collective rebound, with peers Hengrui Pharma up 5.82%, CSPC Pharma up 2.48%, and Hansoh Pharma up 2.16%, signaling a broad-based sector recovery following sustained selling pressure in recent sessions. The rebound comes after the company announced on June 15 a share buyback plan of up to HK$2 billion over the next 12 months, explicitly stating that the company's value is currently severely underestimated. The company executed approximately HK$49.23 million in buybacks on June 16, purchasing 10.512 million shares at prices between HK$4.66 and HK$4.69 per share.

The buyback plan is backed by the company's HK$33 billion cash reserves and net cash position of HK$16.9 billion. Since March, the founding family has continuously increased holdings by nearly HK$70 million, reinforcing confidence signals. The stock had previously been weighed down by a short-selling ratio as high as 24.21% and sector-wide weakness, with Morgan Stanley having lowered its target price from HK$8.3 to HK$7.8 while maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)